ASCO in Action

ASCO in Action provides the latest news and analysis related to critical policy issues affecting the cancer community, updates on the Association for Clinical Oncology’s ongoing advocacy efforts, and opportunities for members and others in the cancer care community to take action.

To sign up for advocacy alerts, log in to with your member or guest account, and visit the subscription center available under your account profile.

Tune in to the ASCO in Action podcast series for analysis and commentary on cancer policy and practice issues. The podcast is available through iTunes or Google Play.

Showing results for Advocacy

June 29, 2020

The Association for Clinical Oncology (ASCO) recently sent a letter to congressional leadership urging more action to address current drug shortages exacerbated by COVID-19 and to prevent future drug shortages. Specifically, ASCO encouraged Congress to take the following actions to help mitigate drug shortages:

June 23, 2020

The Association for Clinical Oncology (ASCO) continues to advocate for federal and state legislative action to guarantee Medicaid coverage of routine care costs (like laboratory tests and physician visits) for clinical trial participants. Medicaid is the only major insurer that is not required to cover these costs, which means that patients with life-threatening conditions do not have access to the best – and sometimes only—treatment option for their condition.

June 18, 2020

The Association for Clinical Oncology (ASCO) joined more than 100 other health organizations in sending a letter to congressional leadership urging them to include the targeted and limited liability protections in the bipartisan “Coronavirus Provider Protection Act” (H.R. 7059) in the next COVID-19 relief package.

June 18, 2020

The Association for Clinical Oncology (ASCO) recently submitted comments to the Department of Defense (DoD) in response to the TRICARE Coverage and Payment for Certain Services in Response to the COVID–19 Pandemic interim final rule. The rule allows TRICARE to reimburse providers for audio-only services during the COVID-19 Public Health Emergency (PHE).

June 16, 2020

On June 12, the U.S. Department of Health and Human Services (HHS) released a final rule establishing changes to Section 1557 of the Affordable Care Act (ACA), which prohibits discrimination on the basis of race, color, national origin, sex, age, or disability in certain health programs or activities.

June 9, 2020

Earlier this month, the Association for Clinical Oncology (ASCO) Board approved its 2020 Advocacy Priorities, which will help ensure that patients with cancer and survivors have access to value-based, high-quality cancer care. The overarching goals of the priorities are to:

June 8, 2020

The Association for Clinical Oncology (ASCO) recently submitted a letter to the Centers for Medicare & Medicaid Services (CMS) regarding the Policy and Regulatory Revisions in Response to the COVID-19 Public Health Emergency (CMS-1744-IFC) interim final rule.

May 12, 2020

ALEXANDRIA, Va. -- Twenty-seven practices elevated their standard of care and achieved Quality Oncology Practice Initiative (QOPI®) Certification in the first quarter of this year. The Association for Clinical Oncology (Association) commends these practices that have demonstrated their commitment to providing the highest-quality oncology care to their patients, communities, and contemporaries.

May 12, 2020

The Association for Clinical Oncology (ASCO) recently sent a letter to House and Senate leadership urging their support for policies to increase diversity in clinical trials, including the CLINICAL TREATMENT Act (H.R. 913), in a future COVID-19 response package.

April 28, 2020

The Association for Clinical Oncology (ASCO) joined hundreds of other health organizations in signing onto four separate letters to Congress regarding future COVID-19 legislation as part of an effort to ensure patient access to high-quality, high-value cancer care during the pandemic. The four comment letters address different areas of cancer care delivery system:  

April 23, 2020

The American Society of Clinical Oncology (the Society) and its affiliate organization the Association for Clinical Oncology (the Association) today announced the results of a survey that tracked the initial impact of the COVID-19 pandemic on cancer clinical trials, highlighted a new research initiative to address the data gap on the coronavirus’ effect on individuals with cancer, and set forth a road to recovery as the cancer care delivery system prepares for life after COVID-19.

April 22, 2020

WHAT: The U.S. cancer care delivery system is facing unprecedented challenges during the COVID-19 pandemic. Cancer care teams and the patients they serve are navigating significant barriers to high-quality care and impossibly difficult choices regarding allocation of potentially life-saving medical resources to critically ill patients.

March 30, 2020

In testimony submitted to Congress about the federal budget for FY 2021, ASCO thanked lawmakers for increasing funding for cancer research in FY2020 and urged them  to increase funding for the National Institutes of Health (NIH), the National Cancer Institute (NCI), the Food and Drug Administration (FDA), and the Centers for Disease Control and Protection (CDC) in the year ahead.

March 17, 2020

The Association for Clinical Oncology (ASCO) recently submitted comments in response to Part II of the Centers for Medicare & Medicaid Services’ (CMS) calendar year 2021 Advance Notice of Methodological Changes for Medicare Advantage Capitation Rates and Part C and Part D Payment Policies. The advance notice proposes updates and changes to the methodologies used to pay Medicare Advantage plans, Programs of All-Inclusive Care for the Elderly organizations, and Part D sponsors.

March 17, 2020

The Association for Clinical Oncology (ASCO) recently held a briefing on Capitol Hill to inform policymakers and other stakeholders about the need for the bipartisan CLINICAL TREATMENT Act (H.R. 913), which would guarantee coverage of the routine care costs for Medicaid enrollees with life-threatening conditions participating in clinical trials.